Members |
acceptabilityId |
4A1 |
Acceptable (foundation metadata concept) |
4A2 |
Acceptable (foundation metadata concept) |
4B |
Acceptable (foundation metadata concept) |
4C |
Acceptable (foundation metadata concept) |
4D (four dimensional) ultrasonography |
Acceptable (foundation metadata concept) |
4D (four dimensional) ultrasound |
Acceptable (foundation metadata concept) |
4D (four dimensional) ultrasound scan |
Acceptable (foundation metadata concept) |
4Fr |
Acceptable (foundation metadata concept) |
4H leukodystrophy |
Preferred (foundation metadata concept) |
4H leukodystrophy (disorder) |
Preferred (foundation metadata concept) |
4H post incubation |
Acceptable (foundation metadata concept) |
4H post peritoneal dialysis |
Acceptable (foundation metadata concept) |
4H specimen |
Acceptable (foundation metadata concept) |
4H specimen |
Acceptable (foundation metadata concept) |
4H syndrome |
Acceptable (foundation metadata concept) |
4KB5 |
Acceptable (foundation metadata concept) |
4a |
Preferred (foundation metadata concept) |
4a-hydroxytetrahydrobiopterin dehydratase |
Preferred (foundation metadata concept) |
4a-hydroxytetrahydrobiopterin dehydratase (substance) |
Preferred (foundation metadata concept) |
4ab |
Preferred (foundation metadata concept) |
4b |
Preferred (foundation metadata concept) |
4c |
Preferred (foundation metadata concept) |
4d |
Preferred (foundation metadata concept) |
4e |
Preferred (foundation metadata concept) |
4f |
Preferred (foundation metadata concept) |
4p minus syndrome |
Acceptable (foundation metadata concept) |
4p partial monosomy syndrome |
Preferred (foundation metadata concept) |
4p partial monosomy syndrome (disorder) |
Preferred (foundation metadata concept) |
4p partial trisomy syndrome |
Preferred (foundation metadata concept) |
4p partial trisomy syndrome (disorder) |
Preferred (foundation metadata concept) |
4p16.3 microduplication syndrome |
Preferred (foundation metadata concept) |
4p16.3 microduplication syndrome (disorder) |
Preferred (foundation metadata concept) |
4q partial monosomy syndrome |
Preferred (foundation metadata concept) |
4q partial monosomy syndrome (disorder) |
Preferred (foundation metadata concept) |
4q partial trisomy syndrome |
Preferred (foundation metadata concept) |
4q partial trisomy syndrome (disorder) |
Preferred (foundation metadata concept) |
4q21 microdeletion syndrome |
Preferred (foundation metadata concept) |
4q21 microdeletion syndrome (disorder) |
Preferred (foundation metadata concept) |
4q25 proximal deletion syndrome |
Preferred (foundation metadata concept) |
4q25 proximal deletion syndrome (disorder) |
Preferred (foundation metadata concept) |
4th |
Acceptable (foundation metadata concept) |
4th floor |
Acceptable (foundation metadata concept) |
4th generation HIV ELISA |
Acceptable (foundation metadata concept) |
4th left lumbar vein |
Acceptable (foundation metadata concept) |
4th nerve palsy |
Acceptable (foundation metadata concept) |
4th right lumbar vein |
Acceptable (foundation metadata concept) |
4x/wk |
Acceptable (foundation metadata concept) |
5 |
Preferred (foundation metadata concept) |
5 |
Preferred (foundation metadata concept) |
5 (qualifier value) |
Preferred (foundation metadata concept) |
5 French gauge |
Preferred (foundation metadata concept) |
5 French gauge (qualifier value) |
Preferred (foundation metadata concept) |
5 IU/0.1mL |
Acceptable (foundation metadata concept) |
5 International Units in 0.1mL |
Preferred (foundation metadata concept) |
5 International Units in 0.1mL (qualifier value) |
Preferred (foundation metadata concept) |
5 alpha-cholest-8(9)-en-3 beta-ol |
Acceptable (foundation metadata concept) |
5 aza 2 desoxycytidine |
Acceptable (foundation metadata concept) |
5 azacytidine |
Acceptable (foundation metadata concept) |
5 azadeoxycytidine |
Acceptable (foundation metadata concept) |
5 hours |
Preferred (foundation metadata concept) |
5 hours (qualifier value) |
Preferred (foundation metadata concept) |
5 level of presenting part in relation to ischial spines |
Preferred (foundation metadata concept) |
5 level of presenting part in relation to ischial spines (finding) |
Preferred (foundation metadata concept) |
5 o'clock position |
Preferred (foundation metadata concept) |
5 o'clock position (qualifier value) |
Preferred (foundation metadata concept) |
5 o'clock position on mammogram |
Preferred (foundation metadata concept) |
5 o'clock position on mammogram (finding) |
Preferred (foundation metadata concept) |
5 times a week |
Acceptable (foundation metadata concept) |
5% Acetic acid |
Preferred (foundation metadata concept) |
5% Acetic acid (substance) |
Preferred (foundation metadata concept) |
5' Nucleotidase measurement |
Preferred (foundation metadata concept) |
5' Nucleotidase measurement (procedure) |
Preferred (foundation metadata concept) |
5' acylphosphoadenosine hydrolase |
Preferred (foundation metadata concept) |
5' acylphosphoadenosine hydrolase (substance) |
Preferred (foundation metadata concept) |
5'-exonuclease |
Acceptable (foundation metadata concept) |
5'-methylthioadenosine phosphorylase |
Preferred (foundation metadata concept) |
5'-methylthioadenosine phosphorylase (substance) |
Preferred (foundation metadata concept) |
5'-nucleotidase |
Preferred (foundation metadata concept) |
5'-nucleotidase (substance) |
Preferred (foundation metadata concept) |
5'-polynucleotidase |
Acceptable (foundation metadata concept) |
5,10-Methylenetetrahydrofolate reductase (FADH>2<) measurement |
Preferred (foundation metadata concept) |
5,10-Methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) measurement |
Acceptable (foundation metadata concept) |
5,10-Methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) measurement (procedure) |
Preferred (foundation metadata concept) |
5,10-Methylenetetrahydrofolate reductase deficiency |
Preferred (foundation metadata concept) |
5,10-Methylenetetrahydrofolate reductase deficiency (disorder) |
Preferred (foundation metadata concept) |
5,10-methenyltetrahydrofolate synthetase |
Acceptable (foundation metadata concept) |
5,10-methylenetetrahydrofolate reductase (FADH>2<) |
Preferred (foundation metadata concept) |
5,10-methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) |
Acceptable (foundation metadata concept) |
5,10-methylenetetrahydrofolate reductase (reduced flavin adenine dinucleotide) (substance) |
Preferred (foundation metadata concept) |
5,10-methylenetetrahydrofolate reductase gene analysis |
Preferred (foundation metadata concept) |
5,10-methylenetetrahydrofolate reductase gene analysis (procedure) |
Preferred (foundation metadata concept) |
5,25-dihydroxy cholecalciferol |
Preferred (foundation metadata concept) |
5,25-dihydroxy cholecalciferol (substance) |
Preferred (foundation metadata concept) |
5,6-dihydrouracil |
Preferred (foundation metadata concept) |
5,6-dihydrouracil (substance) |
Preferred (foundation metadata concept) |
5,8,11,14-eicosatetraenoic acid |
Acceptable (foundation metadata concept) |
5,8,11-eicosatrienoic acid |
Preferred (foundation metadata concept) |
5,8,11-eicosatrienoic acid (substance) |
Preferred (foundation metadata concept) |
5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase |
Preferred (foundation metadata concept) |
5-(3,4-diacetoxybut-1-ynyl)-2,2'-bithiophene deacetylase (substance) |
Preferred (foundation metadata concept) |
5-15 questionnaire |
Preferred (foundation metadata concept) |